Molecular mechanism of bortezomib in mantle cell lymphoma
10.3760/cma.j.issn.1009-9921.2011.03.019
- VernacularTitle:硼替佐米治疗套细胞淋巴瘤的分子学机制
- Author:
Bingrui ZHAO
- Publication Type:Journal Article
- Keywords:
Bortezomib;
Lymphoma,mantle-cell;
Molecular mechanism of action
- From:
Journal of Leukemia & Lymphoma
2011;20(3):185-187
- CountryChina
- Language:Chinese
-
Abstract:
Mantle cell lymphoma is a distinct subtype of non-Hodgkin lymphoma (NHL) that remains incurable with the shortest survival time. Bortezomib is the first proteasome inhibitor used for the treatment of hematological malignant diseases, such as multiple myeloma and relapse or refractory mantle cell lymphoma (MCL). Investing the mechanism of bortezomib for MCL, including modulation of cell cycle, the influence of cell apoptosis, the disturbance of the MCL microenvironment and the cooperative action with other antineoplastic drugs, is helpful to make the treatment strategy for MCL.
